by The global Gene and Cell Therapies Targeting CNS Disorders Market is estimated to be valued at US$ 8.2 Bn in 2023 and is expected to exhibit a CAGR of 30% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Gene and cell therapies use genetic material or living cells to treat diseases. They have potential to transform treatment of complex CNS disorders like Alzheimer’s, Parkinson’s, stroke, spinal cord injury, multiple sclerosis etc by correcting underlying genetic defects, replacing missing/damaged cells or modulating immune system. These therapies aim to repair damaged neurons, stimulate regeneration of brain cells or protect functioning cells from further damage. They provide personalized treatment by tailoring therapy for each individual.
Market key trends:
One of the major trends in the market is the strong focus on personalized medicine. Researchers are developing gene therapies that are tailored to each patient’s specific genetic mutation, increasing the therapy’s effectiveness and precision. Advancements in molecular diagnostics allow identifying the exact genetic variants responsible for diseases. This enables development of personalized gene and cell therapies targeting only the problematic genes and variations. Other trends include growing research in cell-based therapies using stem cells for regeneration of neurons and non-embryonic stem cells for modulating immune system. Increased funding from private and public sources is also fueling development of novel therapies for previously untreatable disorders.
Porter’s Analysis
Threat of new entrants: The Gene And Cell Therapies Targeting Cns Disorders Market requires huge R&D investments and clinical trials which make it difficult for new players to enter the market.
Bargaining power of buyers: The bargaining power of buyers is moderate as the treatment options for CNS disorders are limited.
Bargaining power of suppliers: Suppliers have moderate bargaining power due to the specialized reagents and materials required for Gene and Cell Therapies.
Threat of new substitutes: Gene And Cell Therapies face low threat of substitutes as there are limited treatments options for CNS disorders.
Competitive rivalry: The Gene And Cell Therapies Targeting CNS Disorders Market experiences high competitive rivalry due to the presence of major players.
Key Takeaways
The Global Gene And Cell Therapies Targeting Cns Disorders Market Size is expected to witness high growth at a CAGR of 30% over the forecast period, due to increasing prevalence of neurological disorders and rising investment in R&D.
Regional analysis: North America dominates the global market due to presence of major market players and advanced healthcare infrastructure. Asia Pacific exhibits the fastest growth owing to rising geriatric population and improving healthcare facilities.
Key players: Key players operating in the Gene And Cell Therapies Targeting Cns Disorders Market are Novartis, Brainstorm Cell Therapeutics, Helminth, Core stem, Q therapeutics, Helminth, Rapa Therapeutics, Brainstorm Cell Therapeutics, Neuroblast, Osteocyte, Ferrer International, Neuralstem, Ferrer International, Semeia Cell Technologies, Labella Gene Therapeutics, Sangamon Therapeutics, Hoffmann-La Roche, Longeron, Soi Gene Therapies, Prevail Therapeutics (Eli Lilly and Company), Aerogeneration, Brain Neurotherapy Bio (Ask Bio), Unique Biopharma, Neurogenic Inc., Passage Bio, AXOVANT SCIENCES GMBH, Meira Tx Limited, Asclepios Biopharmaceutical (Ask Bio), Biogen, Sarepta Therapeutics, REGENXBIO Inc., Lysogen, Voyager Therapeutics, PTC Therapeutics.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
